Medication adherence in patients with cardiovascular disease: current view of the problem

In this article the authors address the problem of poor medication adherence in patients with cardiovascular disease. Poor medication adherence significantly reduces efficacy of pharmacotherapy thus increasing risk of cardiovascular complications and higher treatment costs in routine clinical practice. This problem was first raised by a few foreign scientists in the 90s and then officially recognized by the World Health Organization in 2003. The article presents review on the prevalence of low medication adherence in patients with cardiovascular disease and describes key factors associated with decreased adherence. An overview of widely used indirect methods to measure medication adherence is presented as well. On the way to solve this problem, the development and implementation of various measures and interventions to improve medication adherence is actively carried out in recent years. The results of the most significant studies on the effectiveness of such interventions are also presented in the article. Positive influence on patient adherence was demonstrated, however, only a number of studies reported reduction of the risk of unfavorable clinical outcomes of cardiovascular diseases. This confirms the need to further study the problem of medication adherence focusing on routine clinical practice in Russia.

medication adherence, methods to measure adherence, interventions to improve adherence, cardiovascular disease, coronary heart disease

1. World Health Organization (2004) Atlas of Heart Disease and Stroke, Vol. 2015. WHO, Geneva.

2. WHO media centre. Cardiovascular diseases. http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 10 Jan 2016).

3. Okrainec K, Banerjee DK & Eisenberg MJ. Coronary artery disease in the developing world. American Heart Journal. 2004;148(1):7-15. DOI:10.1016/j.ahj.2003.11.027

4. Baroletti S & Dell’Orfano H. Medication Adherence in Cardiovascular Disease. Circulation. 2010;121(12):1455-1458.

5. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882-7.

6. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015;131:e29—322.

7. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern. 2005;143:659-72.

8. Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2010;17:261-70.

9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.

10. Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.

11. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682-92.

12. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.

13. Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532-40.

14. Briffa TG, Hobbs Ms, Tonkin A, et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2011;4:107-13.

15. World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO, 2003.

16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. DOI:10.1111/j.1524-4733.2007.00213.x.

17. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2014:(11);1-730.

18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care.2005;43:521-30.

19. Lambert EV, Steyn K, Stender S, et al. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006;16:286-91.

20. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007;167:1798-803.

21. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.

22. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412-424.

23. Cutler DM, EverettW. Thinking outside the pillbox-medication adherence as a priority for health c.are reform. N Engl J Med. 2010;362:15531555.

24. Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013;309:2105-2106.

25. Ascertaining Barriers for Compliance: Policies for Safe, Effective and Cost-effective Use of Medicines in Europe. ABC Project newsletter [Internet]. 2009; Available from: http://abcproject.eu/img/ABC_newsletter_06_03_2009.pdf (29 July 2013).

26. Schmittdiel JA, Nichols GA, Dyer W, et al. Health care system-level factors associated with performance on Medicare STAR adherence metrics in a large, integrated delivery system. Med Care. 2015;53(4):332-7.

27. Chowdhuiy R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-8.

28. Bowty AD, shrank WH, Lee JL, et al. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med. 2011;26:1479-91.

29. Laba T-L, Bleasel J, Brien J-A. Strategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged populations: a systematic review. International Journal of Cardiology. 2013;167(6):2430-2440.

30. Demonceau J, Ruppar T, Kristanto P, et al. Identification and assessment of aherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545-62.

31. Chen H-Y, Saczynski JS, Lapane KL, Kiefe CI, & Goldberg RJ. Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review. Heart & Lung: The Journal of Acute and Critical Care. 2015;44(4):299-308. DOI: 10.1016/j.hrtlng.2015.02.004

32. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028-1036.

33. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-1847.

34. Newby LK, LaPointe NMA, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.

35. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.

36. Zullig LL, Ramos K & Bosworth H.B. Improving Medication Adherence in Coronary Heart Disease. Current Cardiology Reports. 2017;19(11). DOI:10.1007/s11886-017-0918-y

37. Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. European Journal of Clinical Pharmacology. 2011;67(4):407-414.

38. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. European Heart Journal. 2013;34(38):2940-2948. DOI: 10.1093/eurheartj/eht295

39. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.

40. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-576

41. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662-1666

42. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459-466

43. Rosenbaum L. Beyond belief — how people feel about taking medications for heart disease. N Engl J Med. 2015;372:183-7.

44. Santo K, Kirkendall S, Laba T-L, et al. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Preventive Cardiology 2016;23(10):1065-1076. DOI: 10.1177/2047487316638501

45. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345-56.

46. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol. 2002;54:212-20.

47. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150:1377-8.

48. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-10.

49. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.

50. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418-425.

51. Lukina YV, Kutishenko NP, Martsevich SY. Treatment adherence: modern view on a well known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-95. DOI: 10.15829/1728-8800-2017-1-91-95

52. Spilker B. Methods of assessing and improving compliance in clinical trials. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press. 1991:37-56.

53. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-77. [Erratum, Ann Intern Med 2002;136:175.].

54. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004-6.

55. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures. Annals of Pharmacotherapy. 2006;40 (7-8),1280—1288. DOI:10.1345/aph.1h018.

56. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641.

57. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking. London: NCCSDO. 2005;40-6.

58. Nunes V, Neilson J, O’Flynn N, et al. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: NICE 2009.

59. Čulig (Culig), Josip & Leppée, Marcel. From Morisky to Hill-Bone; self-reports scales for measuring adherence to medication. Collegium antropologicum. 2014;38:55-62.

60. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.

61. Wang Y, Lee J, Tang WE, Toh MP, Ko Y. Validity and reliability of a self-reported measure of medication adherence in patients with Type 2 diabetes mellitus in Singapore. Diabet Med. 2012;29:338-44.

62. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348-54.

63. Risser J, Jacobson TA, Kripalani S. Development and Psychometric Evaluation of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) in Low-Literacy Patients With Chronic Disease. Journal of Nursing Measurement. 2007;15(3):203-219. DOI: 10.1891/106137407783095757

64. Nguyen T-M-U, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring a systematic review. British Journal of Clinical Pharmacology. 2014;77(3),:427-445. DOI: 10.1111/bcp.12194

65. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.

66. Willey C, Redding C, Stafford J, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22: 858-71.

67. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30:169-75.

68. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17:17-32.

69. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32: 749-54.

70. Schroeder K, Fahey T, Hay AD, Montgomery A, Peters TJ. Adherence to antihypertensive medication assessed by self-report was associated with electronic monitoring compliance. J Clin Epidemiol. 2006;59:650-1.

71. Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008; 31:2037-43.

72. Schuz B, Wurm S, Ziegelmann JP, et al. Changes in functional health, changes in medication beliefs, and medication adherence. Health Psychol. 2011;30:31-9.

73. Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59-66.

74. Wang Y, Kong MC, Ko Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin. Thromb Haemost. 2012;108:1-7.

75. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Summer. 2000;15:90-6.

76. Fodor GJ, Kotrec M, Bacskai K, Dorner T, Lietava J, Sonkodi S, Rieder A, Turton P. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens 2005; 23: 1261—6.

77. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846—57.

78. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999; 37: 113—24.

79. Hahn SR, Park J, Skinner EP, Yu-Isenberg KS,Weaver MB, Crawford B, Flowers PW. Development of the ASK-20 adherence barrier survey. Curr Med Res Opin 2008; 24: 2127—38.

80. Matza LS, Yu-Isenberg KS, Coyne KS, Park J,Wakefield J, Skinner EP,Wolever RQ. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin 2008; 24: 3197—206.

81. Matza LS, Park J, Coyne KS, Skinner EP, Malley KG, Wolever RQ. Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother 2009; 43: 1621—30.

82. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health 2009; 12: 118—23.

83. Unni EJ, Farris KB. Development of a new scale to measure self-reported medication nonadherence. Res Social Adm Pharm. 2015 MayJun;11(3):e133-43. doi: 10.1016/j.sapharm.2009.06.005. Epub 2009 Oct 9..

84. Fernandez S, Chaplin W, Schoenthaler AM, Ogedegbe G. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med 2008; 31: 453—62.

85. Ogedegbe G,Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. J Clin Epidemiol 2003; 56: 520—9.

86. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004; 38: 1363—8.

87. van de Steeg N, Sielk M, Pentzek M, Bakx C, Altiner A. Drug-adherence questionnaires not valid for patients taking blood-pressure-lowering drugs in a primary health care setting. J Eval Clin Pract 2009; 15: 468—72.

88. Toll BA,McKee SA,Martin DJ, Jatlow P, O’Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine Tob Res 2007; 9: 597—605.

89. Hill-Briggs F, Gary TL, Bone LR, Hill MN, Levine DM, Brancati FL. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol 2005; 24: 349—57.

90. Vik SA, Maxwell CJ, Hogan DB, Patten SB, Johnson JA, RomonkoSlack L. Assessing medication adherence among older persons in community settings. Can J Clin Pharmacol 2005; 12: 152—64.

91. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A,Weaver C, Bennett S, Investigators NN-P, Coordinators. Self-reported adherence versus pill count in Parkinson’s disease: the NET-PD experience. Mov Disord 2007; 22: 822—7.

92. Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 2007; 69: 158—64.

93. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, DunbarJacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43: 1203—7.

94. Gatti ME, Jacobson KL, Gazmararian JA, Schmotzer B, Kripalani S. Relationships between beliefs about medications and adherence. Am J Health Sys Pharm 2009; 66: 657—64.

95. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42: 241—7.

96. Haynes RB, McDonald H, GargAX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database SystRev. 2002;(2):CD000011.

97. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:I16-I18.

98. Cramer JA. Optimizing long-term patient compliance. Neurology 1995;45:Suppl 1:S25-S28.

99. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care 1997;8(4):43-54.

100. Connor J, Rafter N and Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935—939.

101. Fuller, R. H., Perel, P., Navarro-Ruan, T., Nieuwlaat, R., Haynes, R. B., & Huffman, M. D. (2018). Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart, 104(15), 1238—1243. doi:10.1136/heartjnl-2017-312571.

102. Jiang X, Sit JW and Wong TK. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: Evidence from Chengdu, China. J Clin Nurs 2007; 16: 1886—1897.

103. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: A randomized clinical trial. JAMA Intern Med 2014; 174: 186—193.

104. Ma Y, Ockene IS, Rosal MC, et al. Randomized trial of a pharmacistdelivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol 2010; 2010: 383281. DOI: 10.1155/2010/383281.

105. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: Results from the FOCUS project. J Am Coll Cardiol 2014; 64: 2071—2082.

106. Khonsari S, Subramanian P, Chinna K, et al. Effect of a reminder system using an automated short message service on medication adherence following acute coronary syndrome. Eur J Cardiovasc Nurs 2015; 14: 170—179.

107. Rinfret S, Rodes-Cabau J, Bagur R, et al. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart 2013; 99: 562—569.

108. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365: 2088—2097.

109. Bond C. The MEDMAN study: A randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007; 24: 189—200.

110. Gould KA. A Randomized Controlled Trial of a Discharge Nursing Intervention to Promote Self-Regulation of Care for Early Discharge Interventional Cardiology Patients. Dimens Crit Care Nurs. 2011 MarApr;30(2):117-25. doi: 10.1097/DCC.0b013e3182052324.

111. Park LG, Howie-Esquivel J, Chung ML, et al. A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Educ Couns 2014; 94: 261—268.

112. Xavier D, Gupta R, Kamath D, et al. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:244—53.

113. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918.